Island Pharmaceuticals Ltd (AU:ILA) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Island Pharmaceuticals Ltd has initiated the Phase 2a segment of its groundbreaking PROTECT trial, administering an attenuated dengue virus to subjects as part of a study aimed at finding a preventative and therapeutic solution for the globally rampant dengue fever. The trial is distinguished by its dual-phased approach, assessing both prophylactic and therapeutic responses to the virus, with full Phase 2a results expected by year-end and Phase 2b set to start early 2025. The company is also hosting an investor webinar to discuss the trial’s progress and other company developments, including a new antiviral acquisition.
For further insights into AU:ILA stock, check out TipRanks’ Stock Analysis page.